Skin treatments developer Syntopix says that a potential global consumer healthcare partner for the SYN1113 acne treatment has decided not to move forward with the treatment.
The rights to the treatment will all revert to Syntopix. Positive trial results have been achieved. A version that is combined with salicylic acid is rapidly absorbed into the skin.
Collaborations with Sinclair Pharma and Nivea manufacturer Beiersdorf are continuing.
At 54.5p a share, Syntopix is valued at £5.84m.
© 2021 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.